Why has the Resmed share price crashed 19% in a week?

The sleep-focused ASX 200 healthcare stock has been harshly punished over the past week.

| More on:
A man lies in bed wide awake in the middle of the night.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a horrid week so far for the Resmed Inc (ASX: RMD) share price, no two ways about it. For one, the US-based healthcare share lost a nasty 4.63% yesterday, closing the session at $27.42 a share.

Since last Thursday (3 August), the Resmed share price has plunged from $33.85, a nasty 19% decline.

What on earth has gone so wrong for Resmed shares that have seen its shareholders take a near-20% cut in the value of their holdings in just a week?

Well, it appears all of the negativity stems from the full-year results that Resmed released, you guessed it, last Friday.

What's caused this collapse in the Resmed share price?

As we covered at the time, Resmed reported an 18% rise in revenues to US$4.2 billion. Net income was also up 18% to US$229.7 million.

However, it appears investors are being put off by Resmed's falling gross margins. The company revealed that its gross margin had fallen by 80 basis points to 55.8%. This in turn led to an earnings per share (EPS) metric of US$6.09. That was 9 cents below what the markets were estimating.

So it appears that investors have been spooked by this latest earnings report, and have pulled the bottom out from the Resmed share price accordingly over the past week.

But perhaps it's not all bad news for Resmed investors. As we covered earlier this week, ASX broker Citi has retained a buy rating on the sleep-focused company, with a 12-month share price target of $39. That would see Resmed gain more than 41% from the current share price if Citi is on the money here.

The broker acknowledged that it was disappointed with what it saw last week. However, Citi reckons the margin compression is only temporary and is set to rebound this financial year.

Let's see if the broker is right on the Resmed share price in a year's time.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Botanix Pharmaceuticals share price on watch amid FDA news and 'transformative event'

Big news has just been announced from this clinical dermatology company.

Read more »

Three health professionals at a hospital smile for the camera.
52-Week Highs

3 ASX healthcare shares smashing new 52-week highs today

The buying continues for these healthcare darlings.

Read more »

woman sitting at desk holding hand up in stop motion
Healthcare Shares

Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision

The ASX All Ords stock is awaiting an important announcement from the US FDA.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Is the slashed Sonic Healthcare share price a 'buying opportunity'?

Is this stock a healthy opportunity?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.
Healthcare Shares

Buy the ASX 200 healthcare stock with 'decades of growth ahead'

This healthcare giant is well positioned for growth, experts say.

Read more »